Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study

被引：61

作者：

Gomez, Virginia Esamilla ^{[1
]}

Garcia-Gutierrez, Valentin ^{[2
]}

Corral, Lucia Lopez ^{[3
]}

Cadenas, Irene Garcia ^{[4
]}

Martinez, Ariadna Perez ^{[5
]}

Malaver, Francisco J. Marquez ^{[1
]}

Caballero-Velazquez, Teresa ^{[1
]}

Sierra, Pedro A. Gonzalez ^{[6
]}

Alegria, Maria C. Viguria ^{[7
]}

Salinas, Ingrid M. Parra ^{[8
]}

Cabrera, Cristina Calderon ^{[1
]}

Vicent, Marta Gonzalez ^{[9
]}

Torres, Nancy Rodriguez ^{[1
]}

Porras, Rocio Parody ^{[10
]}

Coll, Christelle Ferra ^{[11
]}

Orti, Guillermo ^{[12
]}

Ferreiras, David Valcarcel ^{[12
]}

Llanza, Rafael De la Camara ^{[13
]}

Moles, Paula ^{[14
]}

Velazquez-Kennedy, Kyra ^{[2
]}

Mende, Maria Joao ^{[3
]}

Barrigon, Dolores Caballero ^{[3
]}

Perez, Estefania ^{[3
]}

Bofarull, Rodrigo Martino ^{[4
]}

Gerosa, Silvanna Saavedra ^{[4
]}

Sierra, Jorge ^{[4
]}

Poch, Marc ^{[5
]}

Ripa, Maria T. Zudaire ^{[7
]}

Perez, Miguel A. Diaz ^{[9
]}

Angulo, Blanca Molina ^{[9
]}

Ortega, Isabel Sanchez ^{[10
]}

Caballer, Jaime Sanz ^{[14
]}

Gomez, Juan Montoro ^{[14
]}

Tocino, Ildefonso Espigado ^{[1
]}

Perez-Simon, Jose A. ^{[1
]}

机构：

[1] Univ Seville, Univ Hosp Virgen Rocio, Inst Biomed IBIS CSIC CIBERONC, Dept Hematol,CB16 12 00480, Seville, Spain

[2] Univ Hosp Ramon y Cajal, IRYCIS, Dept Hematol, Madrid, Spain

[3] Complejo Asistencial Univ Salamanca IBSAL, Ctr Invest Canc IBMCC, Salamanca, Spain

[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[5] Clin Univ Hosp Valencia, Valencia, Spain

[6] Univ Hosp, Granada, Spain

[7] Hosp Navarra, Navarra, Spain

[8] Univ Hosp Miguel Servet, Zaragoza, Spain

[9] Hosp Nino Jesus, Madrid, Spain

[10] Inst Catala Oncol Hospitalet, Barcelona, Spain

[11] Inst Catala Oncol Germans Trias, Badalona, Spain

[12] Univ Hosp Vall dHebron, Barcelona, Spain

[13] Hosp La Princesa, Madrid, Spain

[14] Hosp La Fe, Valencia, Spain

来源：

BONE MARROW TRANSPLANTATION | 2020年 / 55卷 / 03期

关键词：

CONSENSUS DEVELOPMENT PROJECT; AVAILABLE THERAPY; CLINICAL-TRIALS; RAPAMYCIN; IBRUTINIB; RESISTANT; CRITERIA;

D O I：

10.1038/s41409-019-0731-x

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1-5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1-10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23-67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63-89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.

引用

页码：641 / 648

页数：8

共 33 条

[1] Treatment of Patients with Steroid Refractory Acute Graft Vs Host Disease (SR-GvHD): A Matched Paired Analysis of Anti-CD26 (Begelomab) Compared to Other Treatment [J].

Bacigalupo, Andrea ;

Deeg, H. Joachim ;

Caballero, Dolores ;

Gualandi, Francesca ;

Raiola, Anna Maria ;

Varaldo, Riccardo ;

Di Grazia, Carmen ;

Corral, Lucia Lopez ;

van Lint, Maria Teresa .

BLOOD, 2016, 128 (22)

[2] Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review [J].

Benden, Christian ;

Haughton, Maria ;

Leonard, Saoirse ;

Huber, Lars C. .

JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (09) :921-933

[3] Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease [J].

Benito, AI ;

Furlong, T ;

Martin, PJ ;

Anasetti, C ;

Appelbaum, FR ;

Doney, K ;

Nash, RA ;

Papayannopoulou, T ;

Storb, R ;

Sullivan, KM ;

Witherspoon, R ;

Deeg, HJ .

TRANSPLANTATION, 2001, 72 (12) :1924-1929

[4] Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis [J].

Chen, Xiaomei ;

Wang, Chunyan ;

Yin, Jin ;

Xu, Jinhuan ;

Wei, Jia ;

Zhang, Yicheng .

PLOS ONE, 2015, 10 (08)

[5] Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect [J].

Choi, Jaebok ;

Cooper, Matthew L. ;

Alahmari, Bader ;

Ritchey, Julie ;

Collins, Lynne ;

Holt, Matthew ;

DiPersio, John F. .

PLOS ONE, 2014, 9 (10)

[6] Rituximab for steroid-refractory chronic graft-versus-host disease [J].

Cutler, Corey ;

Miklos, David ;

Kim, Haesook T. ;

Treister, Nathaniel ;

Woo, Sook-Bin ;

Bienfang, Don ;

Klickstein, Lloyd B. ;

Levin, Jesse ;

Miller, Katherine ;

Reynolds, Carol ;

Macdonell, Rebecca ;

Pasek, Mildred ;

Lee, Stephanie J. ;

Ho, Vincent ;

Soiffer, Robert ;

Antin, Joseph H. ;

Ritz, Jerome ;

Alyea, Edwin .

BLOOD, 2006, 108 (02) :756-762

[7] Therapy with mycophenolate mofetil for refractory acute and chronic GVHD [J].

Furlong, T. ;

Martin, P. ;

Flowers, M. E. D. ;

Carnevale-Schianca, F. ;

Yatscoff, R. ;

Chauncey, T. ;

Appelbaum, F. R. ;

Deeg, H. J. ;

Doney, K. ;

Witherspoon, R. ;

Storer, B. ;

Sullivan, K. M. ;

Storb, R. ;

Nash, R. A. .

BONE MARROW TRANSPLANTATION, 2009, 44 (11) :739-748

[8] Rapamycin for Refractory Acute Graft-Versus-Host Disease [J].

Ghez, David ;

Rubio, Marie Therese ;

Maillard, Natacha ;

Suarez, Felipe ;

Chandesris, Marie-Olivia ;

Delarue, Richard ;

Deau-Fischer, Benedicte ;

Varet, Bruno ;

Hermine, Olivier ;

Buzyn, Agnes .

TRANSPLANTATION, 2009, 88 (09) :1081-1087

[9] The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms [J].

Greenfield, Graeme ;

McPherson, Suzanne ;

Mills, Ken ;

McMullin, Mary Frances .

JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16

[10] Extracorporeal photopheresis in acute and chronic graft-versus-host disease [J].

Greinix, Hildegard T. ;

Worel, Nina ;

Just, Ulrike ;

Knobler, Robert .

TRANSFUSION AND APHERESIS SCIENCE, 2014, 50 (03) :349-357

← 1 2 3 4 →